| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Infectious Diseases |
Recent Updates
Recently added Catalysts
Salarius Pharmaceuticals, Inc.$0.84
+0.13 (+18.98%)
D 30Pipeline Score Overvalued Biotech · Clinical
Market Cap
5.36 M
EPS
-39.23
P/E Ratio
-
Value Trade
4.69 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
749.81 K
Operating CF
-2.89 M
Total Assets
8.42 M
Total Liabilities
4.55 M
Equity
3.88 M
D/E Ratio
12,345
27.27 %
Week
-3.25 %
1 Month
-79.51 %
3 Month
-92.73 %
6 Month
-99.97 %
5 Year
-100 %
All Time
Cash Data
Cash Position
7.82 M
Monthly Burn
963.00 K
Runway
5.9 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
6.05 M
52 Week Range
0.51 - 108
% held by Insiders
3.52 %
% held by Institutions
11.4 %
Enterprise Value
553.03 K
Total Shares
5.86 M
Short %
30.65 %
Float Shares
5.85 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-05-29 | Cavhanza (nilotinib) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-05-29 | Cavhanza (nilotinib) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-05-29 | Cavhanza (nilotinib) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
D30
Pipeline Score $1M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 33%
Micro Cap (rank 612 of 912)
Percentile RankSalarius Pharmaceuticals, Inc. faces pipeline headwinds (30/100), with $245M risk-adjusted pipeline value, led by SP-3164 in Lymphoma, Non-Hodgkin's, Adult (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SP-3164 Small molecule | Lymphoma, Non-Hodgkin's, Adult | Phase 1 | NCT05979857 | 10% | $147M | NOT YET_RECRUITING | 72 | AVERAGE | D (36) | Aug 15, 2027 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
seclidemstat | myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) | Phase 1/2 | 2025-02-03 | response rate: 43%; overall survival: 18.5 months; event free survival: 7.2 months; overall survival range: 6.1-30.9 months; event free survival range: 6.3-8.2 months; typical overall survival after failure: four to six months Read More | Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers Read More | |
seclidemstat | myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) | Phase 1/2 | 2025-02-03 | response rate: 43%; overall survival: 18.5 months; event free survival: 7.2 months; overall survival range: 6.1-30.9 months; event free survival range: 6.3-8.2 months; typical overall survival after failure: four to six months Read More | Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers Read More | |
seclidemstat | myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) | Phase 1/2 | 2025-02-03 | response rate: 43%; overall survival: 18.5 months; event free survival: 7.2 months; overall survival range: 6.1-30.9 months; event free survival range: 6.3-8.2 months; typical overall survival after failure: four to six months Read More | Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SLRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SLRX ranks across every disease it competes inCompetitive Position is a premium feature
See how SLRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial